Browsing Tag
Boston Scientific
23 posts
Could THUNDERBOLT sharpen Penumbra’s stroke portfolio before the Boston Scientific deal closes?
Find out how Penumbra’s THUNDERBOLT FDA clearance could reshape stroke thrombectomy and computer assisted clot removal.
Penumbra (NYSE: PEN) says STORM-PE 90-day data strengthens case for thrombectomy in pulmonary embolism
Penumbra’s new STORM-PE data showed stronger 90-day recovery in pulmonary embolism patients. Read what it means for growth, competition, and care.
Will Carisa Schultz’s appointment help Nuwellis manage its cash crunch and regain trust?
Nuwellis appoints Carisa Schultz as CFO amid stock volatility and strategic expansion. Learn what this leadership change means for investors and medtech peers.
Boston Scientific to acquire Penumbra for $14.5bn in transformative vascular and neurovascular expansion move
Boston Scientific’s $14.5B acquisition of Penumbra signals an aggressive move into neurovascular and thrombectomy markets. Find out what this means for medtech.
Haemonetics (NYSE: HAE) acquires Vivasure Medical in €185m deal to expand vascular closure portfolio for structural heart procedures
Haemonetics acquires Vivasure Medical to expand its hospital closure portfolio with PerQseal Elite. Find out what this means for structural heart growth.
Can AI predict heart failure years earlier? Inside Anumana’s breakthrough AHA 2025 results
Anumana’s FDA-cleared ECG-AI platform enhances heart failure prediction and expands into perioperative care with Boston Scientific’s backing. Learn more.
Boston Scientific to take full control of Nalu Medical in $533m chronic pain tech deal
Boston Scientific is acquiring Nalu Medical for $533M to expand its pain therapy portfolio with a miniaturized, wearable neurostimulation system. Learn what this means.
Is neuromodulation entering its next growth cycle? Lessons from Medtronic, Axonics, and Boston Scientific
Neuromodulation is moving into its next growth cycle. Explore how Medtronic, Boston Scientific, and Axonics are reshaping bladder control and chronic care.
From stigma to scale: How bladder control therapies are evolving from hidden struggle to healthcare priority
Bladder control therapies are moving from stigma to mainstream care. Discover how rising awareness and innovation are reshaping treatment options globally.
Boston Scientific to expand cardiovascular portfolio with Bolt Medical acquisition
Boston Scientific Corporation has announced a definitive agreement to acquire Bolt Medical, Inc., a developer of cutting-edge intravascular…